Royalty Report: Medical, cardiac, Device – Collection: 28946

$150.00

Curated Royalty Rate Report
Category: Technology Licenses, Created On: 2022-04-28, Record Count: 10

Description

This collection of transactions and supporting information was developed using our AI algorithm to curate similar royalty reports into a cohesive collection to support your licensing, transfer pricing or other transaction scenarios where documented royalty rates and/or deal terms are important.
Category: Technology Licenses
Created On: 2022-04-28
Record Count: 10

Primary Industries

  • Medical
  • cardiac
  • Device
  • Supply
  • Therapeutic
  • Drugs
  • Disease
  • Pharmaceuticals
  • Regenerative medicine
  • Specialty
  • Surgical

IPSCIO Report Record List

Below you will find the records curated into this collection.  This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs.  The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms.  For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report

IPSCIO Record ID: 28946

License Grant
The Israel Licensors hereby grants to the Licensee the exclusive, royalty-bearing right and license in the Territory under the Licensee's Intellectual Property (including, for clarity, a sublicense under the Sublicensed IP) to Develop, Manufacture and Commercialize Products for use in the Field.
License Property
The Licensor owns or controls certain intellectual property rights covering a liquid polymer composed of Sodium Alginate and Ca-D-Gluconate (designated by BioLineRx as “BL-1040”).  The Licensor is currently developing the Product (as defined below) as a medical device for the direct treatment of cardiac tissue following acute myocardial infarction.

Bioabsorbable cardiac matrix, or BCM, is currently in a placebo-controlled clinical trial designed to support CE mark registration in the European Union.

BCM is a medical device intended to prevent congestive heart failure following a STEMI, which is a type of severe heart attack.

BCM is delivered during a minimally invasive, commonly performed cardiac procedure called a percutaneous coronary intervention procedure. BCM is a formulated sterile solution of sodium alginate and calcium gluconate designed to be administered as a liquid through the coronary artery. When administered following a STEMI, BCM flows into damaged heart muscle where, in the presence of abnormally high extracellular calcium released by the damaged cells, it forms a protective hydrogel meshwork within the wall of the heart’s left ventricle. Based on pre-clinical animal studies, we believe that BCM has the potential to act as a flexible scaffold to provide physical support to the ventricle wall in the early stages of recovery following a STEMI and prevent further structural damage while the heart muscle heals. In addition, in our pre-clinical animal studies, as calcium levels in the damaged area returned to normal, BCM dissolved and was excreted through normal kidney function.

Field of Use
The Licensee is developing BCM for the prevention of cardiac remodeling, which often leads to congestive heart failure following an ST-segment elevated myocardial infarction, or STEMI.

IPSCIO Record ID: 7203

License Grant
The Licensor entered into an exclusive, worldwide out-licensing arrangement with the Licensee, in regards to BL-1040.

The Licensee is obligated to use commercially reasonable efforts to complete clinical development of, and to commercialize, BL-1040 or a product related thereto for use in the prevention, mitigation and treatment of injury to the myocardial tissue of the heart.

License Property
BL-1040, is a novel resorbable polymer solution for use in the prevention of cardiac remodeling in patients who suffered an AMI. Preventing cardiac remodeling following an AMI may prevent transition to congestive heart failure and/or improve patient survival over the long term. Following an AMI, BL-1040 is administered via intracoronary injection. Upon contact with damaged cardiac tissue, the liquid BL-1040 transitions into a gel within the infarcted cardiac tissue and forms a “scaffold” that supports, retains the shape of, and enhances the mechanical strength of the heart muscle during the recovery and repair phases following an AMI.
Field of Use
BL-1040 is being developed as a class III medical device under the FDA’s pre-marketing approval, regulatory pathway.

The Licensee commenced Preservation1, a CE Mark registration clinical trial of BL-1040, now called “Bioabsorbable Cardiac Matrix,” or BCM by the Licensee. Preservation 1 aims to evaluate the safety and effectiveness of BL-1040 (BCM) for prevention of ventricular remodeling and congestive heart failure when administered following AMI.

IPSCIO Record ID: 2719

License Grant
Seller shall sell, transfer, assign, convey, deliver, license or sublicense, as specified below, to Buyer, or shall cause to be sold, transferred, assigned, conveyed, delivered, licensed or sublicensed, as specified below, to Buyer, and Buyer shall acquire all of Seller’s right, title and interest in and to the properties and assets of Seller.
Field of Use
The Licensee would acquire all rights to the cardiovascular products, including related trademarks, patents, intellectual property, product inventory and other related assets consisting of Cardene® I.V. (nicardipine hydrochloride), Cardene SR® and new formulations of Cardene in development, as well as Retavase® (reteplase) and the development product ularitide.  Cardene®  is for the short-term treatment of hypertension when oral therapy is not feasible or desirable. Cardene I.V. is the only intravenous calcium channel blocker (calcium ion influx inhibitor) for this indication.  Cardene I.V. offers rapid, precise blood pressure control and has been proven to be as effective as sodium nitroprusside with fewer dose adjustments (1).  Cardene I.V. prevents calcium ions from entering cardiac and vascular smooth muscle cells (the cells that line the arteries) through specific ion channels in the cell membrane. When these channels are blocked, calcium cannot enter the cell, thereby preventing the vascular smooth muscle from contracting.  Retavase® (reteplase) is a fibrinolytic agent for the management of acute myocardial infarction (AMI) or heart attack in adults for the improvement of ventricular function following AMI, the reduction of the incidence of congestive heart failure and the reduction of mortality associated with AMI. Treatment. Retavase, a recombinant plasminogen activator, works by generating plasmin, an enzyme produced naturally by the body’s blood plasma. Plasmin breaks down fibrin, a major constituent of blood clots, thereby helping to dissolve the clots.

IPSCIO Record ID: 372578

License Grant
The original agreement between the Licensor of Sweden and Licensee is for selective inhibition ADP compound known as Cangrelor.

This amendment addresses performing the CHAMPION-PHOENIX Study, and financial considerations.

License Property
Cangrelor, a potent intravenous adenosine diphosphate-receptor antagonist, significantly reduced the rate of ischemic events, including stent thrombosis, during PCI without increasing severe bleeding when compared with clopidogrel, according to a late-breaking trial presented here.

CHAMPION-PHOENIX Study shall mean a repeat phase III prospective, randomized, double blind, standard clopidogrel care controlled, parallel group, superiority study in which the primary objective is to demonstrate that the efficacy of Cangrelor ( combined with 600mg of clopidogrel) is superior to that of usual care, in patients requiring percutaneous coronary intervention (PCI) as measured by a composite of all cause mortality, myocardial infarction (Ml), IDR and stent thrombosis which will be performed under US IND 56,812.

Ticagrelor Product shall mean Licensor s pharmaceutical product containing the pharmaceutical compound known as ticagrelor, a reversibly binding oral P2Y12 adenosine di phosphate (ADP) receptor antagonist.

Field of Use
The field of use is in patients undergoing percutaneous coronary intervention or PCI.  Cangrelor is used during percutaneous coronary intervention (PCI) for reducing the risk of heart attacks.  Percutaneous coronary intervention (PCI) refers to a family of minimally invasive procedures used to open clogged coronary arteries (those that deliver blood to the heart). By restoring blood flow, the treatment can improve symptoms of blocked arteries, such as chest pain or shortness of breath.

IPSCIO Record ID: 257717

License Grant
The parties are adverse parties following currently pending litigation matters, which are being terminated pursuant to a Settlement Agreement.

The parties are engaged in, inter alia, the design, development, manufacture, and sale of CRM Products.

Pursuant to the Settlement Agreement, the parties have agreed to terminate certain cases and have agreed to enter into a cross licensing of certain rights under the Licensed Patents and Sublicensable Patents.

Licensor grants a non-exclusive, irrevocable, perpetual, worldwide license or sublicense, as the case may be, without the right to sublicense, under all Licensed Patents of Licensor to make, have made, use, sell, have sold, offer to sell, distribute, have distributed, and otherwise dispose of CRM Products, including supplying or causing to be supplied components thereof for use therein, and further including importing CRM Products, including components thereof for use therein, into any jurisdiction where Licensed Patents of Licensor are effective.

Licensor grants the right and option for a period of thirty (30) months from the Effective Date to obtain a non-exclusive, worldwide, non-transferable, royalty-bearing license under the CIC Patents.

License Property
CRM Products means devices for monitoring or electrically stimulating or shocking the heart which are suitable for chronic implantation, in whole or in part, by or with human patients. The term CRM Products includes, without limitation cardiac pacemakers, antitachycardia pacemakers, cardiac resynchronization therapy systems, cardioverters, and defibrillators, including combinations thereof; loop recording systems, implantable cardiac monitoring systems, implantable hemodynamic monitoring systems, pulse generators and other waveform generators for such devices; cardiac lead implant catheters and associated tools; leads, electrodes, sensors, capacitors, batteries, power sources, and all other components for such devices; mechanisms for coupling such generators in a stimulating, shocking, sensing, or monitoring relationship to the heart; and data dispensing, processing, and gathering systems for such devices, including programmers, pacing system analyzers, defibrillation system analyzers, testers, encoders, decoders, transtelephonic and other remote monitoring systems and services for use with implantable devices, transmitters, receivers, and computer software-controlled systems, and including the software.
Field of Use
The field of use is the pacemaker monitoring industry.

IPSCIO Record ID: 257804

License Grant
The parties are adverse parties following currently pending litigation matters, which are being terminated pursuant to a Settlement Agreement.

The parties are engaged in, inter alia, the design, development, manufacture, and sale of CRM Products.

Pursuant to the Settlement Agreement, the parties have agreed to terminate certain cases and have agreed to enter into a cross licensing of certain rights under the Licensed Patents and Sublicensable Patents.

Licensor grants a non-exclusive, irrevocable, perpetual, worldwide license or sublicense, as the case may be, without the right to sublicense, under all Licensed Patents of Licensor to make, have made, use, sell, have sold, offer to sell, distribute, have distributed, and otherwise dispose of CRM Products, including supplying or causing to be supplied components thereof for use therein, and further including importing CRM Products, including components thereof for use therein, into any jurisdiction where Licensed Patents of Licensor are effective.

Licensor shall grant the right and option until the expiration of thirty (30) months from the Effective Date or ninety (90) days from the date Licensor exercises its option, whichever is later in time, to obtain a non-exclusive, worldwide, non-transferable, license under the specific Patents.

License Property
CRM Products means devices for monitoring or electrically stimulating or shocking the heart which are suitable for chronic implantation, in whole or in part, by or with human patients. The term CRM Products includes, without limitation cardiac pacemakers, antitachycardia pacemakers, cardiac resynchronization therapy systems, cardioverters, and defibrillators, including combinations thereof; loop recording systems, implantable cardiac monitoring systems, implantable hemodynamic monitoring systems, pulse generators and other waveform generators for such devices; cardiac lead implant catheters and associated tools; leads, electrodes, sensors, capacitors, batteries, power sources, and all other components for such devices; mechanisms for coupling such generators in a stimulating, shocking, sensing, or monitoring relationship to the heart; and data dispensing, processing, and gathering systems for such devices, including programmers, pacing system analyzers, defibrillation system analyzers, testers, encoders, decoders, transtelephonic and other remote monitoring systems and services for use with implantable devices, transmitters, receivers, and computer software-controlled systems, and including the software.
Field of Use
The field of use is the medical (pacemaker) industry.

IPSCIO Record ID: 230517

License Grant
The Licensor granted the Kuwait Licensee the exclusive right to the intellectual property for the licensed use and development in Kuwait and other GCC/Middle East countries.
License Property
The Intellectual Property relates to methods of repairing damaged heart tissue by transplanting myoblasts that express SDF-1 and other therapeutic proteins capable of recruiting other stem cells within a patient’s own body to the cell transplant area.

The IP includes products and technologies like MyoCell for the treatment of heart damage. These are autologous muscle-derived cellular therapies designed to populate regions of scar tissue within a patient’s heart with new living cells for the purpose of improving cardiac function in chronic heart failure patients.

MyoCell is an innovative clinical therapy designed to populate regions of scar tissue within a patient’s heart with autologous muscle cells, or cells from a patient’s body, for the purpose of improving cardiac function in chronic heart failure patients.

Field of Use
The intent is to offer regenerative treatment options to patients, based on Licensor products and technologies like MyoCell and MyoCell SDF-1.

IPSCIO Record ID: 3610

License Grant
Licensors grant Licensee an exclusive, worldwide, royalty-bearing right and license, with a right to sub-license, to the rights of Licensors under the Patent.
License Property
Products means a diaphragm or patch and improvements thereto for SAVR the 'Patch' and all Patch products and accessories such as holders, strips of pericardium, sizers, sutures and improvements thereto and kits sold for use in a surgical procedure in which the chest is opened to rebuild, reconstruct or remodel the anterior ventricular wall.

IPSCIO Record ID: 6393

License Grant
We entered into an agreement that provides us an exclusive, worldwide right to individually use or to sell or lease to medical practitioners and related healthcare entities the following items, for the treatment of acute MI and heart failure, or the Field of Use.
License Property
TGI 1200 is a patient-derived cell therapy for the treatment of acute myocardial infarction, chronic heart ischemia, and lower limb ischemia utilizing the Adipose Tissue Processing System. It is a fully automated device for the rapid processing of patient derived fat tissue for use in Acute MI, Lower Limb Ischemia and Chronic Ischemia and certain disposable products used in conjunction with the devices, or, the TGI Licensed Product Candidates; processes that use the TGI Licensed Product Candidates, or the TGI Licensed Processes; and the cells derived using the TGI Licensed Product Candidates and/or the TGI Licensed Processes, or the TGI Licensed Cells.
Field of Use
Field of Use
  â€¢   the TGI 1200 and certain disposable products used in conjunction with the devices, or, the TGI Licensed Product Candidates;
  â€¢   processes that use the TGI Licensed Product Candidates, or the TGI Licensed Processes; and
  â€¢   the cells derived using the TGI Licensed Product Candidates and/or the TGI Licensed Processes, or the TGI Licensed Cells.

The TGI 1200 system is a compact, fully automated cell isolation device for the rapid processing of patient-derived fat tissue to separate, isolate and produce large yields of endothelial progenitor and stem cells. The fat tissue is extracted from the patient using a minor liposuction-like procedure and processed using the TGI 1200. We anticipate that the TGI 1200 will process cells within a one-hour time period. Fully automated device for the rapid processing of patient derived fat tissue for use in Acute MI, Lower Limb Ischemia and Chronic Ischemia.  We are seeking to develop the TGI 1200, a patient-derived cell therapy for the treatment of acute MI utilizing Bioheart’s TGI 1200 adipose tissue processing system.  1200 is being designed to be used for the treatment of heart muscle damage immediately following a heart attack. We hope to demonstrate that the injection of endothelial progenitor and stem cells derived from fat tissue by the TGI 1200 is a safe and effective means of limiting or reversing some of the effects of acute MI and preventing or slowing a patient’s progression from MI to CHF. Fat tissue is an abundant and readily available source of endothelial progenitor and stem cells and is easily extractable from a patient using minimally invasive techniques.

IPSCIO Record ID: 435

License Grant
The license agreement grants us exclusive, worldwide, licenses to specified rights relating to the CORrestore patch and related products and accessories for SAVR.
License Property
We are developing the CorRestore(TM) patch, a new cardiac implant for use in heart surgeries called surgical anterior ventricular restoration, or SAVR.  During SAVR, the surgeon restores, or remodels, an enlarged, poor functioning left ventricle to more normal size and function by inserting an implant, in most instances, or closing the defect directly.

The CorRestore Patch component is made from bovine pericardium (cow heart-sac tissue) and is designed to standardize the implantation during cardiac repair. Soft and flexible, the CorRestore Patch has a rigid inner ring that is surrounded by a contoured outer rim to provide a seal against leaks at the perimeter.

Disclaimer: The information gathered from RoyaltySource® database was sourced from the U.S. Securities and Exchange Commission EDGAR Filings and other public records. While we believe the sources to be reliable, this does not guarantee the accuracy or completeness of the information provided. Further, the information is supplied as general guidance and is not intended to represent or be a substitute for a detailed analysis or professional judgment. This information is for private use only and may not be resold or reproduced without permission.